Synereca Pharmaceuticals has received $1.4 million in seed capital from i2E Inc. The Oklahoma City-based company is developing a compound that kills drug resistant bacteria.
“We’ve demonstrated that we have compounds that without shifting toxicity make antibiotics more effective,” Synereca CEO Clayton Duncan said. “We’re going to use this investment to try to advance that set of compounds to improve the efficacy of the Colistin, an older antibiotic, against difficult-to-treat multidrug resistant bacteria. Over 90 percent of these investment dollars will go to research.”
The investment was led by the i2E-managed Oklahoma Seed Capital Fund and Accele Venture Partners with participation by the SeedStep Angels group, also managed by i2E, and Oklahoma Angel investors.